Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma

Sunandana Chandra; Grant A. McArthur; Jeffrey Sosman

doi:10.1007/978-3-030-05070-2_55

Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma

Sunandana Chandra, Grant A. McArthur, Jeffrey Sosman^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

More than 50% of melanomas are BRAF wild-type, that is, they do not harbor a mutation at the BRAFV600 site. This patient population includes those originating from chronic sun-exposed skin, mucosal, and acral sites. BRAF wild-type melanomas have unique pathophysiologic and prognostic features with significant implications in their therapeutic management. Within this melanoma patient population, there are distinct molecular subsets which may be therapeutically targeted providing additional therapeutic options for these patients. However, thus far there have been no breakthrough targetable genomic alterations in the BRAF wild-type melanoma population that have proven to be consistently efficacious.

Original language	English (US)
Title of host publication	Cutaneous Melanoma, Sixth Edition
Publisher	Springer International Publishing
Pages	1087-1108
Number of pages	22
Volume	2
ISBN (Electronic)	9783030050702
ISBN (Print)	9783030050689
DOIs	https://doi.org/10.1007/978-3-030-05070-2_55
State	Published - Jan 1 2020

ASJC Scopus subject areas

General Medicine

Access to Document

10.1007/978-3-030-05070-2_55

Cite this

@inbook{4a874b7bf3e543c081ee54d7b63c3026,

title = "Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma",

abstract = "More than 50% of melanomas are BRAF wild-type, that is, they do not harbor a mutation at the BRAFV600 site. This patient population includes those originating from chronic sun-exposed skin, mucosal, and acral sites. BRAF wild-type melanomas have unique pathophysiologic and prognostic features with significant implications in their therapeutic management. Within this melanoma patient population, there are distinct molecular subsets which may be therapeutically targeted providing additional therapeutic options for these patients. However, thus far there have been no breakthrough targetable genomic alterations in the BRAF wild-type melanoma population that have proven to be consistently efficacious.",

author = "Sunandana Chandra and McArthur, {Grant A.} and Jeffrey Sosman",

note = "Publisher Copyright: {\textcopyright} Springer Nature Switzerland AG 2020.",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/978-3-030-05070-2_55",

language = "English (US)",

isbn = "9783030050689",

volume = "2",

pages = "1087--1108",

booktitle = "Cutaneous Melanoma, Sixth Edition",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma

AU - Chandra, Sunandana

AU - McArthur, Grant A.

AU - Sosman, Jeffrey

PY - 2020/1/1

Y1 - 2020/1/1

N2 - More than 50% of melanomas are BRAF wild-type, that is, they do not harbor a mutation at the BRAFV600 site. This patient population includes those originating from chronic sun-exposed skin, mucosal, and acral sites. BRAF wild-type melanomas have unique pathophysiologic and prognostic features with significant implications in their therapeutic management. Within this melanoma patient population, there are distinct molecular subsets which may be therapeutically targeted providing additional therapeutic options for these patients. However, thus far there have been no breakthrough targetable genomic alterations in the BRAF wild-type melanoma population that have proven to be consistently efficacious.

AB - More than 50% of melanomas are BRAF wild-type, that is, they do not harbor a mutation at the BRAFV600 site. This patient population includes those originating from chronic sun-exposed skin, mucosal, and acral sites. BRAF wild-type melanomas have unique pathophysiologic and prognostic features with significant implications in their therapeutic management. Within this melanoma patient population, there are distinct molecular subsets which may be therapeutically targeted providing additional therapeutic options for these patients. However, thus far there have been no breakthrough targetable genomic alterations in the BRAF wild-type melanoma population that have proven to be consistently efficacious.

UR - http://www.scopus.com/inward/record.url?scp=85150556868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85150556868&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-05070-2_55

DO - 10.1007/978-3-030-05070-2_55

M3 - Chapter

AN - SCOPUS:85150556868

SN - 9783030050689

VL - 2

SP - 1087

EP - 1108

BT - Cutaneous Melanoma, Sixth Edition

PB - Springer International Publishing

ER -

Molecularly Targeted Therapy for Patients with BRAF Wild-Type Melanoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this